Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
![]() |
Recurrent Acute Coronary Syndrome in Young Man with Familial Hypercholesterolemia: Efficacy of Evolocumab Add-On Treatment Demonstrated via Serial Coronary AngiographyBiomedicines, 2024-05, Vol.12 (5), p.1113 [Peer Reviewed Journal]COPYRIGHT 2024 MDPI AG ;2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2227-9059 ;EISSN: 2227-9059 ;DOI: 10.3390/biomedicines12051113 ;PMID: 38791076Full text available |
2 |
Material Type: Article
|
![]() |
Role of miR-128-3p and miR-195-5p as biomarkers of coronary artery disease in Indians: a pilot studyScientific reports, 2024-05, Vol.14 (1), p.11881-11881 [Peer Reviewed Journal]2024. The Author(s). ;The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-024-61077-4 ;PMID: 38789551Full text available |
3 |
Material Type: Article
|
![]() |
The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary diseaseClinical cardiology (Mahwah, N.J.), 2024-05, Vol.47 (5), p.e24284-n/a [Peer Reviewed Journal]2024 The Author(s). published by Wiley Periodicals LLC. ;2024 The Author(s). Clinical Cardiology published by Wiley Periodicals LLC. ;2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0160-9289 ;EISSN: 1932-8737 ;DOI: 10.1002/clc.24284 ;PMID: 38766996Full text available |
4 |
Material Type: Article
|
![]() |
The causal relationship between sarcopenia‐related traits and ischemic stroke: Insights from univariable and multivariable Mendelian randomization analysesCNS neuroscience & therapeutics, 2024-05, Vol.30 (5), p.e14759-n/a [Peer Reviewed Journal]2024 The Authors. published by John Wiley & Sons Ltd. ;2024 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd. ;2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1755-5930 ;EISSN: 1755-5949 ;DOI: 10.1111/cns.14759 ;PMID: 38757378Full text available |
5 |
Material Type: Article
|
![]() |
Identifying risk factors and mortality rate of premature coronary artery disease in young Saudi populationScientific reports, 2024-06, Vol.14 (1), p.12727-12727 [Peer Reviewed Journal]The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2024 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-024-62970-8 ;PMID: 38830947Full text available |
6 |
Material Type: Article
|
![]() |
Osteocalcin: A Potential Marker of Peripheral Arterial Stiffness in Hypertensive PatientsMedicina (Kaunas, Lithuania), 2024-05, Vol.60 (5), p.835 [Peer Reviewed Journal]COPYRIGHT 2024 MDPI AG ;2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1648-9144 ;ISSN: 1010-660X ;EISSN: 1648-9144 ;DOI: 10.3390/medicina60050835 ;PMID: 38793018Full text available |
7 |
Material Type: Article
|
![]() |
Atherogenic index of plasma as a predictor of coronary artery disease: a cohort study in south of IranThe Egyptian heart journal, 2024-05, Vol.76 (1), p.65-65 [Peer Reviewed Journal]The Author(s) 2024 ;2024. The Author(s). ;COPYRIGHT 2024 Springer ;The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1110-2608 ;EISSN: 2090-911X ;DOI: 10.1186/s43044-024-00497-z ;PMID: 38806969Full text available |
8 |
Material Type: Article
|
![]() |
Evolocumab Treatment in Dyslipidemic Patients Undergoing Coronary Artery Bypass Grafting: One-Year Safety and Efficacy ResultsJournal of clinical medicine, 2024-05, Vol.13 (10), p.2987 [Peer Reviewed Journal]COPYRIGHT 2024 MDPI AG ;2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2077-0383 ;EISSN: 2077-0383 ;DOI: 10.3390/jcm13102987 ;PMID: 38792527Full text available |
9 |
Material Type: Article
|
![]() |
A Retrospective Analysis of the Effects of Cardiac Rehabilitation on Health Markers and Performance Outcomes among Diabetic and Non-Diabetic Patients with Coronary Artery Bypass Grafting and Percutaneous Coronary InterventionSports (Basel), 2024-05, Vol.12 (5), p.122 [Peer Reviewed Journal]COPYRIGHT 2024 MDPI AG ;2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2075-4663 ;EISSN: 2075-4663 ;DOI: 10.3390/sports12050122 ;PMID: 38786991Full text available |
10 |
Material Type: Reports
|
![]() |
Cholesterol testMayo Clinic Health Information Library : Tests & Procedures, 20242024 Mayo Foundation for Medical Education and Research (MRMER). All rights reserved.Digital Resources/Online E-Resources |
11 |
Material Type: Reports
|
![]() |
Cholesterol testMayo Clinic Health Information Library : Tests & Procedures, 20242024 Mayo Foundation for Medical Education and Research (MRMER). All rights reserved.Digital Resources/Online E-Resources |
12 |
Material Type: Reports
|
![]() |
Cholesterol testMayo Clinic Health Information Library : Tests & Procedures, 20242024 Mayo Foundation for Medical Education and Research (MRMER). All rights reserved.Digital Resources/Online E-Resources |
13 |
Material Type: Newsletter Article
|
![]() |
Verve Therapeutics (VERV: $5.14) rises 4.9% from 14-day low; +6c [1.2%] Vol Index 1.3 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 31, 2024Digital Resources/Online E-Resources |
14 |
Material Type: Reports
|
![]() |
Cholesterol testMayo Clinic Health Information Library : Tests & Procedures, 20242024 Mayo Foundation for Medical Education and Research (MRMER). All rights reserved.Digital Resources/Online E-Resources |
15 |
Material Type: Newsletter Article
|
![]() |
Verve Therapeutics (VERV: $5.24) hits year-low 16th time in three months; -4c [0.8%]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 29, 2024Digital Resources/Online E-Resources |
16 |
Material Type: Newsletter Article
|
![]() |
Verve Therapeutics (VERV: $5.58) increases on firm volume; +4c [0.7%] Vol Index 1.3 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 23, 2024Digital Resources/Online E-Resources |
17 |
Material Type: Newsletter Article
|
![]() |
Verve Therapeutics (VERV: $5.54) hits year-low 12th time in three months; -41c [6.9%] Vol Index 1.2 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 22, 2024Digital Resources/Online E-Resources |
18 |
Material Type: Newsletter Article
|
![]() |
Verve Therapeutics (VERV: $5.95) hits year-low 11th time in three months; -3c [0.5%] Vol Index 1.3 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 21, 2024Digital Resources/Online E-Resources |
19 |
Material Type: Newsletter Article
|
![]() |
Weekly: Verve Therapeutics (VERV: $5.98) decreases 0.5% on robust volume; -3c [0.5%] Vol Index 1.5 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 20, 2024Digital Resources/Online E-Resources |
20 |
Material Type: Newsletter Article
|
![]() |
Verve Therapeutics (VERV: $5.98) tumbles 6.3% weakening below moving average price; -40c [6.3%] Vol Index 1.8 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 18, 2024Digital Resources/Online E-Resources |